ClearPoint Neuro Earnings Call Transcripts
Fiscal Year 2026
-
Record Q1 2026 revenue of $12.1M (43% growth) driven by organic and IRRAflow contributions, with gross margin up to 64%. 2026 revenue is guided at $52–$56M, all segments expected to grow double digits, and integration synergies are improving margins and global reach.
Fiscal Year 2025
-
2025 saw record revenue growth, a successful IRRAS acquisition, and strong momentum into 2026, with all core segments expected to grow double digits. Guidance for 2026 is $52M–$56M, reflecting FDA and integration factors, and long-term targets remain ambitious.
-
Q3 revenue grew 9% year-over-year to $8.9 million with gross margin rising to 63%. The IRRAS acquisition expands access to a $500 million neurocritical care market, and 2026 combined revenue is forecast at $54–$60 million. Integration and new CRO capacity are expected to drive future growth.
-
Q2 2025 revenue grew 17% year-over-year to $9.2M, driven by strong performance across all segments and record adoption of new products. Cash position strengthened to $41.5M, supporting global expansion and ongoing investments in cell and gene therapy delivery.
-
Q1 2025 revenue grew 11% year-over-year to $8.5M, led by strong gains in neurosurgery navigation and biologics. New funding from Oberland Capital ensures multi-year strategic flexibility, while new product launches and a shift to subscription models position the company for accelerated growth.
Fiscal Year 2024
-
Revenue grew 31% in 2024 to $31.4M, with strong gains across all segments and gross margin rising to 61%. 2025 guidance targets $36–41M revenue, driven by new product launches, global expansion, and increased demand for cell and gene therapy delivery solutions.
-
Q3 2024 saw record revenue of $8.1M, 41% growth, and improved gross margin, with all segments expanding over 20%. Operational cash burn dropped 33%, debt was retired, and guidance remains strong for 2024 and beyond.
-
Record Q2 revenue of $7.9M (32% growth) driven by strong product sales, margin expansion, and global site activations. Full-year guidance raised to $30–$33M, with cash flow breakeven targeted by end of 2025. Seven pharma partners now in FDA expedited programs.